Last reviewed · How we verify
NCT06937957
A Study of BR111 in Patients With Advanced Malignancies
Phase 1 trial testing BR111 for Injection in Advanced Malignancies in 166 participants. Currently enrolling.
9 October 2027
Quick facts
| Lead sponsor | BioRay Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 166 |
| Start date | 24 April 2025 |
| Primary completion | 9 October 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- BR111 for Injection — full drug profile →
- BR111 for Injection — full drug profile →
Conditions studied
- Advanced Malignancies — all drugs for Advanced Malignancies →
Sponsor
BioRay Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06937957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignancies
Currently open trials in the same condition.
- NCT06401356 — An Extension Study for Patients Previously Enrolled in Studies With Pelabresib · Phase 3 · recruiting
- NCT06468098 — A Study of IBI363 in Subjects With Advanced Malignancies · Phase 1 · recruiting
- NCT06717880 — A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer · Phase 1 · recruiting
- NCT05059522 — Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing · Phase 3 · active not recruiting
- NCT04752826 — BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) · Phase 1, PHASE2 · recruiting
Other BioRay Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07498647 — Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia · Phase 2 · not yet recruiting
- NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
- NCT06289894 — A Study of BRY805 in Participants With Advanced Solid Tumors · Phase 1 · terminated
- NCT06126718 — Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx · Phase 1 · completed
- NCT05987605 — Phase I/II Clinical Study of 1A46 Drug Substance · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06937957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioRay Pharmaceutical Co., Ltd.
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06937957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing